NO20082338L - Pyrimidinderivater for behandling av avvikende cellevekst - Google Patents

Pyrimidinderivater for behandling av avvikende cellevekst

Info

Publication number
NO20082338L
NO20082338L NO20082338A NO20082338A NO20082338L NO 20082338 L NO20082338 L NO 20082338L NO 20082338 A NO20082338 A NO 20082338A NO 20082338 A NO20082338 A NO 20082338A NO 20082338 L NO20082338 L NO 20082338L
Authority
NO
Norway
Prior art keywords
treatment
cell growth
aberrant cell
pyrimidine derivatives
mammals
Prior art date
Application number
NO20082338A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Michael Joseph Luzzio
Donn Gregory Wishka
Joel Thomas Arcari
Arthur Douglas Brosius
Kendra Louise Nelson
Gonghua Pan
Jr James Alfred Southers
Jun Xiao
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20082338L publication Critical patent/NO20082338L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Det beskrives en forbindelse av formel (I) eller et farmasøytisk akseptabelt salt derav, hvor Ar er en gruppe av formel (II) og salter derav. Slike pyrimidinderivater er nyttige i behandling av avvikende cellevekst, så som cancer, i pattedyr. Oppfinnelsen vedrører også en fremgangsmåte for å anvende slike forbindelser i behandling av avvikende cellevekst i pattedyr, spesielt mennesker, og farmasøytiske sammensetninger inneholdende slike forbindelser.
NO20082338A 2005-12-21 2008-05-22 Pyrimidinderivater for behandling av avvikende cellevekst NO20082338L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21
PCT/IB2006/003655 WO2007072158A2 (en) 2005-12-21 2006-12-11 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
NO20082338L true NO20082338L (no) 2008-06-25

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082338A NO20082338L (no) 2005-12-21 2008-05-22 Pyrimidinderivater for behandling av avvikende cellevekst

Country Status (30)

Country Link
US (1) US7820648B2 (no)
EP (1) EP1966207A2 (no)
JP (1) JP4332590B2 (no)
KR (1) KR101060051B1 (no)
CN (1) CN101346380B (no)
AP (1) AP2008004488A0 (no)
AR (1) AR058399A1 (no)
AU (1) AU2006327871A1 (no)
BR (1) BRPI0620324A2 (no)
CA (1) CA2634646C (no)
CR (1) CR10095A (no)
DO (1) DOP2006000289A (no)
EA (1) EA014551B1 (no)
EC (1) ECSP088563A (no)
GT (1) GT200600517A (no)
HN (1) HN2006042221A (no)
IL (1) IL191555A0 (no)
MA (1) MA30075B1 (no)
ME (1) MEP0908A (no)
NL (1) NL2000375C2 (no)
NO (1) NO20082338L (no)
PE (1) PE20071138A1 (no)
RS (1) RS20080272A (no)
SV (1) SV2008002969A (no)
TN (1) TNSN08270A1 (no)
TW (1) TW200736258A (no)
UA (1) UA89123C2 (no)
UY (1) UY30051A1 (no)
WO (1) WO2007072158A2 (no)
ZA (1) ZA200804488B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
AP2009005010A0 (en) 2007-04-18 2009-10-31 Pfizer Prod Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
EP2268621A1 (en) * 2008-03-20 2011-01-05 Boehringer Ingelheim International GmbH Regioselective preparation of substituted pyrimidines
JP5551689B2 (ja) 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JP6000273B2 (ja) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー 大環状キナーゼ阻害剤
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
KR20140103925A (ko) 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP2024502174A (ja) * 2021-01-07 2024-01-17 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用
AU2022206470A1 (en) * 2021-01-07 2023-07-27 Ontario Institute For Cancer Research (Oicr) Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
AU2022304597C1 (en) * 2021-07-01 2026-01-29 Alcon Inc. Azetidinyl pyrimidines and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
KR20050084027A (ko) 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
CN102127058A (zh) * 2004-05-14 2011-07-20 辉瑞产品有限公司 治疗异常细胞生长的嘧啶衍生物
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CN101346380A (zh) 2009-01-14
TW200736258A (en) 2007-10-01
AU2006327871A1 (en) 2007-06-28
US7820648B2 (en) 2010-10-26
HN2006042221A (es) 2010-01-18
CA2634646A1 (en) 2007-06-28
UY30051A1 (es) 2007-07-31
RS20080272A (sr) 2009-07-15
EP1966207A2 (en) 2008-09-10
BRPI0620324A2 (pt) 2011-11-08
NL2000375C2 (nl) 2008-01-03
AR058399A1 (es) 2008-01-30
UA89123C2 (ru) 2009-12-25
EA200801287A1 (ru) 2008-10-30
US20080234303A1 (en) 2008-09-25
ZA200804488B (en) 2009-05-27
ECSP088563A (es) 2008-07-30
PE20071138A1 (es) 2007-12-29
MA30075B1 (fr) 2008-12-01
KR101060051B1 (ko) 2011-08-29
CA2634646C (en) 2012-04-10
EA014551B1 (ru) 2010-12-30
JP2009520807A (ja) 2009-05-28
AP2008004488A0 (en) 2008-06-30
WO2007072158A3 (en) 2007-12-27
WO2007072158A8 (en) 2008-08-14
TNSN08270A1 (fr) 2009-10-30
SV2008002969A (es) 2010-08-17
WO2007072158A2 (en) 2007-06-28
JP4332590B2 (ja) 2009-09-16
CN101346380B (zh) 2012-02-29
GT200600517A (es) 2007-09-13
KR20080077026A (ko) 2008-08-20
DOP2006000289A (es) 2007-07-31
NL2000375A1 (nl) 2007-06-25
IL191555A0 (en) 2008-12-29
CR10095A (es) 2008-07-17
MEP0908A (xx) 2010-02-10

Similar Documents

Publication Publication Date Title
MEP0908A (xx) Derivati pirimidina za tretman neprirodnog rasta ćelija
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MY148636A (en) Benzimidazole derivatives
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
WO2011027249A3 (en) Benzimidazole derivatives
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NO20082496L (no) Pyrazinderivater
WO2007135527A3 (en) Benzimidazolyl compounds
TW200833675A (en) Nicotinamide derivatives
NO20092033L (no) Nye forbindelser
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20074703L (no) Antibakterielle piperidinderivater
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
EA200601796A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
WO2007017728A3 (en) Novel heterocyclic compounds
WO2009008345A1 (ja) 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application